SCHEMBL23857721

SCHEMBL23857721

O=CC1Cc2cc(OCCNC(=O)O)nc(Cl)c2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046636 0.86 STK17B (0.38) —
SCHEMBL23871671 0.86 STK17B (0.38) —
SCHEMBL23856482 0.85 — —
SCHEMBL23857342 0.80 — —
SCHEMBL23856660 0.80 ACACB (0.33) —
SCHEMBL23857244 0.80 NPC1 (0.36) —
SCHEMBL23856679 0.79 ALDH1A1 (0.34) —
SCHEMBL30047608 0.79 ALDH1A1 (0.34) —
SCHEMBL23857668 0.76 NPC1 (0.30) —
SCHEMBL23857597 0.75 KMT2A (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 — — EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 — — US disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 — — EP disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 — — WO disclosed
Send feedback